West Pharmaceutical Services, Inc. (WST) Earnings
West Pharmaceutical Services, Inc. is expected to report next earnings on July 23, 2026 (in NaN days), with a consensus EPS estimate of $2.08. WST has beaten EPS estimates in 11 of its last 12 reported quarters (average surprise +19.2% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 23, 2026 | $1.68 | $2.13 | +26.8% | $845M | +8.3% |
| Feb 12, 2026 | $1.83 | $2.04 | +11.5% | $805M | +4.1% |
| Oct 23, 2025 | $1.68 | $1.96 | +16.7% | $804M | +2.4% |
| Jul 24, 2025 | $1.51 | $1.84 | +21.9% | $766M | +5.5% |
| Apr 24, 2025 | $1.22 | $1.45 | +18.9% | $698M | -2.1% |
| Feb 13, 2025 | $1.71 | $1.82 | +6.4% | $749M | +1.1% |
| Oct 24, 2024 | $1.50 | $1.85 | +23.3% | $747M | +5.3% |
| Jul 25, 2024 | $1.74 | $1.52 | -12.6% | $702M | -3.8% |
| Apr 25, 2024 | $1.26 | $1.56 | +23.8% | $695M | +3.7% |
| Feb 15, 2024 | $1.78 | $1.83 | +2.8% | $732M | -1.0% |
| Oct 26, 2023 | $1.86 | $2.16 | +16.1% | $747M | -0.4% |
| Jul 27, 2023 | $1.93 | $2.11 | +9.3% | $754M | -0.4% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · April 23, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Eric Green mentions strong first quarter performance, raised full-year guidance. - HVP components key growth driver, GLP-1 and non-GLP-1 driving growth, orals expanding market. - Biologics business strong, Annex 1 projects growing. - HVP delivery devices organic growth, SmartDOS 3.5 contributing. - West Vantage Dublin site fully operational supporting customer demand.
Guidance
Upgraded full-year 2026 organic revenue growth outlook to 7%-9% (previously 5%-7%), adjusted EPS outlook $8.40-$8.75. Q2 expected revenue $830-$850 million, adjusted diluted EPS $2.05-$2.12.
Segment performance
HVP components (representing 48% of total net sales): organic growth 23%, GLP-1 revenues grew significantly contributing 10% of total company sales, non-GLP-1 HVP components revenues increased in high teens. Biologics: organic growth 26%, NovaPeer strong, Annex 1-related projects up 66% y-o-y. HVP delivery devices (15% of revenues): organic growth 28%, SmartDOS 3.5 revenue growth, non-smart dose parts double-digit growth. Standard products (19% of business): organic growth 0.5%. West Vantage (18% of business): organic growth 6%, Dublin site fully operational.
Risks & headwinds
Macro environment dynamic may affect forecasting; oil and commodity price increases may bring cost pressure but company takes measures to offset.
Analyst Q&A
Q: About acceleration of non-GLPs growth,
A: Biologics and Annex 1 projects growth.
Q: About margin situation,
A: Mix shift and operational execution bring margin improvement.
Q: About customer ordering pattern and Middle East crisis,
A: No pull forward seen.
Q: About capacity bottlenecks and customer capacity transfer,
A: Capacity expansion and multi-site qualification situation.
Q: About Annex 1 customer conversations and conversion,
A: Increasing opportunities, global regulation driving.
Q: About APAC demand environment,
A: Support local consumption and export.
Q: About demand profile of manufacturing space in Dublin and West Coast and other GLP-1 indications,
A: Related progress and demand situation.
Q: About growth driver of Novapure,
A: Market demand for commercialized molecules.
Q: About seasonality of full-year guidance,
A: Impact of CGM contract.
Q: About incremental margin and future opportunities,
A: HPP components business, biologics, Annex 1 and operational excellence bring margin opportunities.
Q: About CEO retirement and successor search,
A: Successor expected to be appointed in second half of year.
Q: About geographical coverage and potential upside of Annex 1,
A: Global customer upgrading trend.
Q: About HVP delivery devices business,
A: Related product portfolio and growth plan